Compounds > snap 37889
Page last updated: 2024-12-09

snap 37889

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1471834
CHEMBL ID210288
CHEMBL ID4522743
SCHEMBL ID916990
SCHEMBL ID8273294
MeSH IDM0498042

Synonyms (56)

Synonym
BIONET1_002696
ht-2157
snap-37889
HMS576C18
1,3-dihydro-1-phenyl-3-[[3-(trilfluoromethyl)phenyl]imino]-2h-indol-2-one
1-(phenyl)-3-{[3-(trifluoromethyl)phenyl]azamethylene}benzo[d]azolidin-2-one
bdbm50187923
1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
CHEMBL210288 ,
AKOS005078094
ht 2157
303149-14-6
snap37889
2h-indol-2-one, 1,3-dihydro-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-
unii-j4drj9bfs1
snap 37889
j4drj9bfs1 ,
1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-1h-indol-2-one
gtpl6126
11L-312S
SCHEMBL916990
SCHEMBL8273294
AC-33591
(e)-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-1,3-dihydro-2h-indol-2-one
ht-2157, (e)-
ww4kzw83bx ,
2h-indol-2-one, 1,3-dihydro-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-, (3e)-
snap-37889, (e)-
unii-ww4kzw83bx
1000273-87-9
HY-100717
CS-6094
1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1h-indol-2-one
txcgmrvpxubhal-uhfffaoysa-n
2h-indol-2-one, 1,3-dihydro-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-, (3z)-
(z)-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)-1,3-dihydro-2h-indol-2-one
EH5R4IAX6Q
ht-2157, (z)-
snap-37889, (z)-
1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)indolin-2-one
BD166856
Q19597525
1000273-85-7
(z)-1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)indolin-2-one
ht-2157; snap-37889; ht2157; snap37889; ht 2157
BCP32884
1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one.
ht-2157(snap37889)
F85480
ht2157
CHEMBL4522743
1-phenyl-3-((3-(trifluoromethyl)phenyl)imino)indolin-2-
txcgmrvpxubhal-plrjnajwsa-n
txcgmrvpxubhal-nceldcmtsa-n
DTXSID701032019
AKOS040758755

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with SNAP 37889 (30 mg/kg, i.p.) reduced operant responding for solutions containing ethanol, sucrose and saccharin."( The galanin-3 receptor antagonist, SNAP 37889, reduces operant responding for ethanol in alcohol-preferring rats.
Ash, BL; Djouma, E; Lawrence, AJ; Williams, SJ; Zanatta, SD, 2011)		0.99

Toxicity

ExcerptReferenceRelevance
" In conclusion, SNAP 37889 is toxic to a variety of cell types independent of GAL3 expression."( In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889.
Beyreis, M; Bianchini, R; Brodowicz, B; Holub, BS; Jakab, M; Kerschbaum, H; Kofler, B; Koller, A; Lang, A; Önder, K; Rid, R; Sternberg, F; Velickovic, O, 2016)		1.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Galanin receptor type 3Homo sapiens (human)Ki0.01700.01700.01700.0170AID267249; AID269267
5-hydroxytryptamine receptor 4Homo sapiens (human)Ki0.07200.00000.443910.0000AID267258
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGalanin receptor type 3Homo sapiens (human)
chemical synaptic transmissionGalanin receptor type 3Homo sapiens (human)
learning or memoryGalanin receptor type 3Homo sapiens (human)
feeding behaviorGalanin receptor type 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGalanin receptor type 3Homo sapiens (human)
galanin-activated signaling pathwayGalanin receptor type 3Homo sapiens (human)
neuropeptide signaling pathwayGalanin receptor type 3Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayGalanin receptor type 3Homo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
maintenance of gastrointestinal epithelium5-hydroxytryptamine receptor 4Homo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 4Homo sapiens (human)
mucus secretion5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
large intestinal transit5-hydroxytryptamine receptor 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
galanin receptor activityGalanin receptor type 3Homo sapiens (human)
peptide hormone bindingGalanin receptor type 3Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneGalanin receptor type 3Homo sapiens (human)
ciliumGalanin receptor type 3Homo sapiens (human)
membraneGalanin receptor type 3Homo sapiens (human)
synapseGalanin receptor type 3Homo sapiens (human)
non-motile ciliumGalanin receptor type 3Homo sapiens (human)
plasma membraneGalanin receptor type 3Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 4Homo sapiens (human)
endosome5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
synapse5-hydroxytryptamine receptor 4Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID267259Agonist activity at human 5HT4 upto 10 uM2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267255Drug level in rat brain at 30 mg/kg, ip after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267258Binding affinity to human 5HT42006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267253Drug level in rat plasma at 10 mg/kg, sc after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267252Drug level in rat brain at 10 mg/kg, sc after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID269268Aqueous solubility at pH 7.42006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
AID267256Drug level in rat plasma at 30 mg/kg, ip after 4 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267250Drug level in rat plasma at 10 mg/kg, pp after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267249Displacement of [125I]galanin from human GAL32006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267260Antagonist activity against human 5HT4 upto 10 uM2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267257Drug level in rat brain at 30 mg/kg, ip after 4 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267254Drug level in rat plasma at 30 mg/kg, ip after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID267251Drug level in rat brain at 10 mg/kg, pp after 2 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
AID269267Displacement of [125I]galanin from human galanin Gal3 receptor2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
AID1345933Human GAL3 receptor (Galanin receptors)2005Proceedings of the National Academy of Sciences of the United States of America, Nov-29, Volume: 102, Issue:48
Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299.
AID1345962Human GAL2 receptor (Galanin receptors)2005Proceedings of the National Academy of Sciences of the United States of America, Nov-29, Volume: 102, Issue:48
Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299.
AID1345933Human GAL3 receptor (Galanin receptors)2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
AID1345933Human GAL3 receptor (Galanin receptors)2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (41.18)29.6817
2010's10 (58.82)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.90 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.0710amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.0810halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.1110C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		2.06101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.0610glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
substance p
[no description available]		2.0510peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		2.0510alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
1,7-phenanthroline
[no description available]		2.0510phenanthroline
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		2.0510benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.0510capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0610aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
galantide
galantide: consists of 20-amino acid residues, 12 AA from the N-terminal of galanin and the C-terminal part of Substance P; blocks the galanin-mediated inhibition of glucose-induced insulin secretion; amino acid sequence given in first source		2.0510
piperidines
Piperidines: A family of hexahydropyridines.		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Alcohol Abuse
[description not available]		02.5320
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.5320
Colonic Inertia
Symptom characterized by the passage of stool once a week or less.		02.1110
Constipation
Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.		02.1110
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.4820
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.3620
Anasarca
[description not available]		02.0510
Angiitis
[description not available]		02.0510
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0510
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.		02.0510
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		02.0610
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		02.4720
Acute Edematous Pancreatitis
[description not available]		02.0610
Acute Disease
Disease having a short and relatively severe course.		02.0610
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		02.0610
Affective Disorders
[description not available]		02.9410
Mood Disorders
Those disorders that have a disturbance in mood as their predominant feature.		02.9410